Clinical Trial

Effects of Different Administration Routes of Dexmedetomidine on Postoperative Sleep Quality in Patients Undergoing Thyroidectomy

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated June 11, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Patients undergoing thyroid surgery often experience significant preoperative anxiety and show high concern about voice changes, scar formation and other related issues. Postoperative neck discomfort and dysphagia also tend to disrupt normal sleep. Dexmedetomidine activates α₂ receptors in the mesencephalic-pontine-medullary reticular formation, inhibits the release of norepinephrine, and induces a sleep state similar to non-rapid eye movement (NREM) sleep, particularly the N2 stage, which is closer to physiological sleep. This study aimed to explore the effects of intranasal spray versus intravenous administration of dexmedetomidine on postoperative sleep quality in patients undergoing thyroidectomy. By optimizing preoperative pharmacological intervention, it intends to improve patients' postoperative sleep quality, relieve pain and reduce postoperative adverse reactions, enhance recovery quality, and optimize patients' satisfaction and comfort level.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-27.
Trial Details
NCT Number NCT07622355
Lead Sponsor The Second People's Hospital of Huai'an
Conditions Thyroid Diseases
Enrollment 120 participants
Start Date 2025-09-01
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-11